Studies on the chemotherapy of human opisthorchiasis: II. Clinical trial of niclofolan.
A clinical trial of Niclofolan on human opisthorchiasis was carried out in 60 patients admitted to the Hospital for Tropical Diseases. Two dosage regimen, 2 mg and 3 mg per kg body weight repeated after a 72 hour interval was administered to 31 and 4 patients respectively. Comparative evaluation with the placebo group of 25 patients was made by the Stoll count on day 20, 40 and 60 after treatment. On day 60 percentage egg reduction of the treated and the placebo groups were similar. Mild and transient side effects such as nausea, anorexia, myalgia and arthralgia were recorded in all 3 groups but more severe in the higher dosage group. In this study, Niclofolan failed in reducing the egg production of Opisthorchis viverrini.
D000293:Adolescent; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009533:Niclofolan / Q000009:adverse effects / Q000627:therapeutic use*; D009596:Nitrophenols / Q000627:therapeutic use*; D009889:Opisthorchiasis / Q000188:drug therapy*; D010270:Parasite Egg Count; D013785:Thailand
D009596:Nitrophenols; D009533:Niclofolan